JP2007517833A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007517833A5 JP2007517833A5 JP2006548308A JP2006548308A JP2007517833A5 JP 2007517833 A5 JP2007517833 A5 JP 2007517833A5 JP 2006548308 A JP2006548308 A JP 2006548308A JP 2006548308 A JP2006548308 A JP 2006548308A JP 2007517833 A5 JP2007517833 A5 JP 2007517833A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- preparation according
- illness
- formulation
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 16
- 201000010099 disease Diseases 0.000 claims description 15
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 4
- 150000002500 ions Chemical class 0.000 claims description 4
- CRJFOPZHQMBHNQ-UHFFFAOYSA-N 1-methyl-2h-pyridine-3-carboxamide Chemical group CN1CC(C(N)=O)=CC=C1 CRJFOPZHQMBHNQ-UHFFFAOYSA-N 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims 13
- 239000000203 mixture Substances 0.000 claims 13
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 7
- 201000001320 Atherosclerosis Diseases 0.000 claims 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 6
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 4
- 238000001356 surgical procedure Methods 0.000 claims 4
- 208000007536 Thrombosis Diseases 0.000 claims 3
- 230000003511 endothelial effect Effects 0.000 claims 3
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 claims 3
- 229960001123 epoprostenol Drugs 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 230000036542 oxidative stress Effects 0.000 claims 3
- 230000002792 vascular Effects 0.000 claims 3
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 2
- 206010048554 Endothelial dysfunction Diseases 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 2
- 208000007107 Stomach Ulcer Diseases 0.000 claims 2
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 2
- 208000029078 coronary artery disease Diseases 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 208000000718 duodenal ulcer Diseases 0.000 claims 2
- 230000008694 endothelial dysfunction Effects 0.000 claims 2
- 201000005917 gastric ulcer Diseases 0.000 claims 2
- 208000006575 hypertriglyceridemia Diseases 0.000 claims 2
- 208000019423 liver disease Diseases 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 208000023761 AL amyloidosis Diseases 0.000 claims 1
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 208000032928 Dyslipidaemia Diseases 0.000 claims 1
- 208000005189 Embolism Diseases 0.000 claims 1
- 208000010228 Erectile Dysfunction Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 206010019799 Hepatitis viral Diseases 0.000 claims 1
- 208000033892 Hyperhomocysteinemia Diseases 0.000 claims 1
- 208000005531 Immunoglobulin Light-chain Amyloidosis Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 208000032382 Ischaemic stroke Diseases 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- 229910002651 NO3 Inorganic materials 0.000 claims 1
- 206010029164 Nephrotic syndrome Diseases 0.000 claims 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 206010036673 Primary amyloidosis Diseases 0.000 claims 1
- 206010049418 Sudden Cardiac Death Diseases 0.000 claims 1
- 201000004810 Vascular dementia Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 230000032683 aging Effects 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 208000037849 arterial hypertension Diseases 0.000 claims 1
- 239000002473 artificial blood Substances 0.000 claims 1
- 210000004204 blood vessel Anatomy 0.000 claims 1
- 230000007211 cardiovascular event Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000020832 chronic kidney disease Diseases 0.000 claims 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 claims 1
- 230000004087 circulation Effects 0.000 claims 1
- 238000007887 coronary angioplasty Methods 0.000 claims 1
- 210000004351 coronary vessel Anatomy 0.000 claims 1
- 208000033679 diabetic kidney disease Diseases 0.000 claims 1
- 235000015872 dietary supplement Nutrition 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 230000002526 effect on cardiovascular system Effects 0.000 claims 1
- 210000003989 endothelium vascular Anatomy 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 238000001631 haemodialysis Methods 0.000 claims 1
- 208000019622 heart disease Diseases 0.000 claims 1
- 230000000322 hemodialysis Effects 0.000 claims 1
- 230000003225 hyperhomocysteinemia Effects 0.000 claims 1
- 201000001881 impotence Diseases 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000004968 inflammatory condition Effects 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 claims 1
- 230000009245 menopause Effects 0.000 claims 1
- 239000002184 metal Substances 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 claims 1
- 235000016709 nutrition Nutrition 0.000 claims 1
- 230000035764 nutrition Effects 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 230000000414 obstructive effect Effects 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 208000028169 periodontal disease Diseases 0.000 claims 1
- 230000003836 peripheral circulation Effects 0.000 claims 1
- 201000011461 pre-eclampsia Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 208000002815 pulmonary hypertension Diseases 0.000 claims 1
- 210000002345 respiratory system Anatomy 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 208000007056 sickle cell anemia Diseases 0.000 claims 1
- 201000002859 sleep apnea Diseases 0.000 claims 1
- 230000000391 smoking effect Effects 0.000 claims 1
- 230000035882 stress Effects 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 208000019553 vascular disease Diseases 0.000 claims 1
- 230000009441 vascular protection Effects 0.000 claims 1
- 201000001862 viral hepatitis Diseases 0.000 claims 1
- 150000003839 salts Chemical class 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- XTEGARKTQYYJKE-UHFFFAOYSA-M Chlorate Chemical compound [O-]Cl(=O)=O XTEGARKTQYYJKE-UHFFFAOYSA-M 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 125000001309 chloro group Chemical class Cl* 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 2
- 229960001860 salicylate Drugs 0.000 description 2
- CFDNDRCKQUQBKN-UHFFFAOYSA-N 1-(1-methylpyridin-1-ium-3-yl)ethanone Chemical class CC(=O)C1=CC=C[N+](C)=C1 CFDNDRCKQUQBKN-UHFFFAOYSA-N 0.000 description 1
- ADRPZEYTIFWCBC-UHFFFAOYSA-N 2-fluoro-n-methyl-n-naphthalen-1-ylacetamide Chemical compound C1=CC=C2C(N(C(=O)CF)C)=CC=CC2=C1 ADRPZEYTIFWCBC-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical class [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 150000002496 iodine Chemical class 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 150000005480 nicotinamides Chemical class 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000003628 tricarboxylic acids Chemical class 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PLP-364348 | 2004-01-12 | ||
| PL04364348A PL364348A1 (en) | 2004-01-12 | 2004-01-12 | Application of quaternary pyridine salts as vessel protection agent |
| PCT/EP2005/050057 WO2005067927A2 (en) | 2004-01-12 | 2005-01-07 | The use of quaternary pyridinium salts as vasoprotective agents |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011233155A Division JP5597179B2 (ja) | 2004-01-12 | 2011-10-24 | 四級ピリジニウム塩の血管保護剤としての使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007517833A JP2007517833A (ja) | 2007-07-05 |
| JP2007517833A5 true JP2007517833A5 (enExample) | 2008-01-17 |
| JP5052138B2 JP5052138B2 (ja) | 2012-10-17 |
Family
ID=34793495
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006548308A Expired - Lifetime JP5052138B2 (ja) | 2004-01-12 | 2005-01-07 | 四級ピリジニウム塩の血管保護剤としての使用 |
| JP2011233155A Expired - Lifetime JP5597179B2 (ja) | 2004-01-12 | 2011-10-24 | 四級ピリジニウム塩の血管保護剤としての使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011233155A Expired - Lifetime JP5597179B2 (ja) | 2004-01-12 | 2011-10-24 | 四級ピリジニウム塩の血管保護剤としての使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (6) | US7935717B2 (enExample) |
| EP (2) | EP1713480B1 (enExample) |
| JP (2) | JP5052138B2 (enExample) |
| CN (1) | CN1905875B (enExample) |
| AT (1) | ATE524179T1 (enExample) |
| AU (1) | AU2005205066C1 (enExample) |
| CA (1) | CA2547234C (enExample) |
| DK (1) | DK1713480T3 (enExample) |
| ES (1) | ES2372756T3 (enExample) |
| PL (2) | PL364348A1 (enExample) |
| PT (1) | PT1713480E (enExample) |
| RU (1) | RU2366420C2 (enExample) |
| WO (1) | WO2005067927A2 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL364348A1 (en) | 2004-01-12 | 2005-07-25 | PHARMENA Sp.z o.o. | Application of quaternary pyridine salts as vessel protection agent |
| ATE548035T1 (de) | 2005-07-11 | 2012-03-15 | Cortria Corp | Formulierungen zur behandlung von lipoprotein- anormalitäten mit einem statin- und einem methylnicotinamid-derivat |
| US20080249140A1 (en) * | 2005-12-09 | 2008-10-09 | Jacques Gosteli | Quaternary 3 -Amido, N-Methylpyridinium Salts as Anti-Inflammatory Agents |
| ES2418153T3 (es) | 2006-03-08 | 2013-08-12 | Cortria Corporation | Terapia de combinación con inhibidores no selectivos de COX para prevenir lesiones gástricas relacionadas con COX |
| EP2079471A2 (en) * | 2006-10-18 | 2009-07-22 | Dermena | Food extracts containing n-methylnicotinamide for treatment of lipoprotein abnormalities and skin diseases and disorders |
| PL381862A1 (pl) * | 2007-02-28 | 2008-09-01 | Trigendo Spółka Z Ograniczoną Odpowiedzialnością | Zastosowanie związków pirydyniowych i sposób leczenia |
| WO2009042440A1 (en) * | 2007-09-28 | 2009-04-02 | Cortria Corporation | 1-methyl nicotinamide and derivatives for treatment of gastric injury |
| PL2211857T3 (pl) * | 2007-10-12 | 2012-11-30 | Politechnika Lodzka | Zastosowanie czwartorzędowych soli pirydyniowych do radioprotekcji |
| PL2211858T3 (pl) | 2007-10-12 | 2015-06-30 | Politechnika Lodzka | Zastosowanie czwartorzędowych soli pirydyniowych do hamowania przerzutów nowotworowych |
| US8304439B1 (en) | 2007-10-12 | 2012-11-06 | Politechnika Lodzka | Use of quaternary pyridinium salts as a therapeutic or preventing agent against ionizing radiation-induced damage |
| AU2009244395A1 (en) * | 2008-05-06 | 2009-11-12 | Cortria Corporation | 1-methylnicotinamide analogs |
| EP2307380B1 (en) * | 2008-07-01 | 2012-10-24 | Politechnika Lódzka | N'-nitroxyalkylnicotinamides for the treatment of cardiovascular diseases |
| WO2010010909A1 (ja) | 2008-07-23 | 2010-01-28 | 東レ株式会社 | 慢性腎不全処置剤 |
| EP2186419A1 (en) * | 2008-11-13 | 2010-05-19 | Tchibo GmbH | NMP-containing extract, a method of its production and uses thereof |
| RU2425672C1 (ru) * | 2010-04-12 | 2011-08-10 | Государственное образовательное учреждение высшего профессионального образования "Курский государственный медицинский университет Федерального агентства по здравоохранению и социальному развитию" | Способ коррекции гипергомоцистеин-индуцированной эндотелиальной дисфункции смесью растворов гомеопатических разведений поликлональных кроличьих антител к эндотелиальной синтазе оксида азота человека - с12, с30, с200 |
| KR101309576B1 (ko) * | 2011-05-25 | 2013-09-17 | 연세대학교 산학협력단 | 대사물질을 이용한 심부전 바이오마커 |
| PL226999B1 (pl) * | 2013-06-11 | 2017-10-31 | Univ Jagiellonski | Azotan (III) 3 -karbamoilo -1-metylopirydyniowy, sposób jego otrzymywania izastosowanie |
| CN105771005A (zh) * | 2016-03-24 | 2016-07-20 | 乐普（北京）医疗器械股份有限公司 | 一种抗风湿性血管狭窄药物支架及其制备方法和应用 |
| WO2018015862A1 (en) | 2016-07-18 | 2018-01-25 | Pharmena S.A. | 1-methylnicotinamide salts for use in raising the blood levels of adiponectin |
| AU2017298648B2 (en) * | 2016-07-18 | 2023-05-11 | Pharmena S.A. | 1-methylnicotinamide for the treatment of diseases associated with C-reactive protein |
| CA3070303A1 (en) * | 2017-07-27 | 2019-01-31 | The Regents Of The University Of Michigan | Plasminogen activator inhibitor-1 (pai-1) inhibitor and method of use |
| PL238932B1 (pl) * | 2017-12-31 | 2021-10-18 | Univ Jagiellonski | Pochodne soli pirydyniowych oraz ich zastosowanie |
| MY210174A (en) * | 2019-01-02 | 2025-08-30 | Celagenex Res India Pvt Ltd | Potent synergistic compositions of vasoactive mediators enhancers for improving vascular endothelial function |
| WO2021205341A1 (en) | 2020-04-07 | 2021-10-14 | Pharmena S.A. | 1-methylnicotinamide for the prevention/treatment of inflammatory airway diseases |
| JP2023542340A (ja) * | 2020-09-21 | 2023-10-06 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 代謝物の免疫学的作用 |
| CN115837023B (zh) * | 2023-02-20 | 2023-05-16 | 中山大学附属第八医院（深圳福田） | 1-甲基烟酰胺在制备抗血管钙化药物中的应用 |
| PL447657A1 (pl) * | 2024-01-31 | 2025-08-04 | Politechnika Poznańska | Czwartorzędowe sole amoniowe zawierające anion 2-furanokarboksylanowy i kation będący alkilową pochodną nikotynamidu, sposób ich otrzymywania i zastosowanie jako środki myjąco-dezynfekujące |
| PL447656A1 (pl) * | 2024-01-31 | 2025-08-04 | Politechnika Poznańska | Nowe czwartorzędowe sole amoniowe zawierające anion pochodzący od kwasu nikotynowego oraz kation N-alkilonikotynamidowy, sposób ich otrzymywania oraz zastosowanie jako substancje o aktywności przeciwbakteryjnej |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB675430A (en) | 1949-07-12 | 1952-07-09 | Cilag Ltd | Novel quaternary nicotinic acid amide derivatives and production thereof |
| DE840698C (de) * | 1949-07-12 | 1952-06-05 | Cilag Aktiengesellschaft | Verfahren zur herstellung neuer derivate des nicotinsaureamids |
| US5260305A (en) | 1988-12-12 | 1993-11-09 | E. R. Squibb & Sons, Inc. | Combination of pravastatin and nicotinic acid or related acid and method for lowering serum cholesterol using such combination |
| US20060263428A1 (en) | 1993-09-20 | 2006-11-23 | Eugenio Cefali | Methods for treating hyperlipidemia with intermediate release nicotinic acid compositions having unique biopharmaceutical characteristics |
| US6406715B1 (en) | 1993-09-20 | 2002-06-18 | Kos Pharmaceuticals, Inc. | Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique urinary metabolite profiles |
| US6676967B1 (en) | 1993-09-20 | 2004-01-13 | Kos Pharmaceuticals, Inc. | Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia |
| US6129930A (en) | 1993-09-20 | 2000-10-10 | Bova; David J. | Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night |
| US6818229B1 (en) | 1993-09-20 | 2004-11-16 | Kos Pharmaceuticals, Inc. | Intermediate release nicotinic acid compositions for treating hyperlipidemia |
| US6746691B2 (en) | 1993-09-20 | 2004-06-08 | Kos Pharmaceuticals, Inc. | Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics |
| US20030157153A1 (en) | 1997-03-06 | 2003-08-21 | Kos Pharmaceuticals, Inc. | Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics |
| US6469035B1 (en) | 1997-07-31 | 2002-10-22 | Eugenio A. Cefali | Methods of pretreating hyperlipidemic individuals with a flush inhibiting agent prior to the start of single daily dose nicotinic acid therapy to reduce flushing provoked by nicotinic acid |
| US20010006644A1 (en) | 1997-07-31 | 2001-07-05 | David J. Bova | Combinations of hmg-coa reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia once a day at night |
| IE970731A1 (en) | 1997-10-07 | 2000-10-04 | Fuisz Internat Ltd | Product and method for the treatment of hyperlipidemia |
| PL190755B1 (pl) | 1999-01-07 | 2006-01-31 | Pharmena Sp Z Oo | Preparat do leczenia i profilaktyki chorób skóry |
| JP2002255846A (ja) * | 2001-02-26 | 2002-09-11 | Sunstar Inc | 経口組成物 |
| CA2341952A1 (en) | 2001-03-23 | 2002-09-23 | Universite Laval | Nicotinic receptor agonists for the treatment of inflammatory pulmonary diseases |
| US20050130990A1 (en) | 2001-03-23 | 2005-06-16 | Universite Laval | Nicotinic receptor agonists for the treatment of inflammatory diseases |
| US8039459B2 (en) | 2004-07-15 | 2011-10-18 | Universite Laval | Nicotinic receptor agonists for the treatment of inflammatory diseases |
| US7153870B2 (en) * | 2003-07-25 | 2006-12-26 | Pfizer Inc. | Nicotinamide derivatives useful as PDE4 inhibitors |
| PL364348A1 (en) | 2004-01-12 | 2005-07-25 | PHARMENA Sp.z o.o. | Application of quaternary pyridine salts as vessel protection agent |
| JP2008519080A (ja) | 2004-11-05 | 2008-06-05 | アリーナ ファーマシューティカルズ， インコーポレイテッド | ナイアシン受容体部分的アゴニストを含む、潮紅および脂質関連障害を処置するための組成物 |
| ATE548035T1 (de) | 2005-07-11 | 2012-03-15 | Cortria Corp | Formulierungen zur behandlung von lipoprotein- anormalitäten mit einem statin- und einem methylnicotinamid-derivat |
| EP2079471A2 (en) | 2006-10-18 | 2009-07-22 | Dermena | Food extracts containing n-methylnicotinamide for treatment of lipoprotein abnormalities and skin diseases and disorders |
| PL381862A1 (pl) | 2007-02-28 | 2008-09-01 | Trigendo Spółka Z Ograniczoną Odpowiedzialnością | Zastosowanie związków pirydyniowych i sposób leczenia |
-
2004
- 2004-01-12 PL PL04364348A patent/PL364348A1/xx unknown
-
2005
- 2005-01-07 WO PCT/EP2005/050057 patent/WO2005067927A2/en not_active Ceased
- 2005-01-07 US US10/585,892 patent/US7935717B2/en active Active
- 2005-01-07 PL PL05726215T patent/PL1713480T3/pl unknown
- 2005-01-07 EP EP05726215A patent/EP1713480B1/en not_active Expired - Lifetime
- 2005-01-07 EP EP10180501A patent/EP2279738A1/en not_active Withdrawn
- 2005-01-07 ES ES05726215T patent/ES2372756T3/es not_active Expired - Lifetime
- 2005-01-07 JP JP2006548308A patent/JP5052138B2/ja not_active Expired - Lifetime
- 2005-01-07 RU RU2006129299/15A patent/RU2366420C2/ru active
- 2005-01-07 AT AT05726215T patent/ATE524179T1/de active
- 2005-01-07 PT PT05726215T patent/PT1713480E/pt unknown
- 2005-01-07 CN CN2005800017124A patent/CN1905875B/zh not_active Expired - Lifetime
- 2005-01-07 AU AU2005205066A patent/AU2005205066C1/en not_active Expired
- 2005-01-07 CA CA2547234A patent/CA2547234C/en not_active Expired - Lifetime
- 2005-01-07 DK DK05726215.6T patent/DK1713480T3/da active
-
2010
- 2010-01-11 US US12/685,377 patent/US8124631B2/en not_active Expired - Lifetime
-
2011
- 2011-04-08 US US13/083,106 patent/US8969391B2/en active Active
- 2011-10-24 JP JP2011233155A patent/JP5597179B2/ja not_active Expired - Lifetime
-
2014
- 2014-06-12 US US14/303,054 patent/US9119844B2/en not_active Expired - Lifetime
-
2015
- 2015-01-16 US US14/598,888 patent/US9333196B2/en not_active Expired - Lifetime
-
2016
- 2016-05-04 US US15/146,485 patent/US9675601B2/en not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007517833A5 (enExample) | ||
| RU2006129299A (ru) | Применение четвертичных солей пиридиния в качестве вазопротекторных средств | |
| JP2019513126A5 (enExample) | ||
| JP2016523243A5 (enExample) | ||
| JP2009531292A5 (enExample) | ||
| JP2011051993A5 (enExample) | ||
| JP2004522714A5 (enExample) | ||
| RU2477132C2 (ru) | Применение четвертичных соединений пиридиния для вазопротекции и/или гепатопротекции | |
| JP2014500243A5 (enExample) | ||
| JP2017522352A5 (enExample) | ||
| BE834794A (fr) | Acide 3-trihydroxygermano-propionique | |
| JP2007518769A5 (ja) | 内皮前駆細胞の刺激並びに臓器の再生及び末端器官障害の進行の抑制のための低用量エリスロポエチンの使用 | |
| JP5558348B2 (ja) | シロスタゾールを含むカルボスチリル誘導体の脂肪肝治療剤 | |
| CN114174255A (zh) | 用于预防和治疗手术后认知功能障碍的化合物 | |
| JPS61254524A (ja) | 抗血栓形成性医薬組成物 | |
| JPH0543698B2 (enExample) | ||
| JP2025160480A (ja) | 不眠症を治療するためのレンボレキサントの使用 | |
| JPS597163A (ja) | 抗動脈硬化剤 | |
| WO1995005825A1 (en) | Circulatory disturbance ameliorant | |
| JP6153264B2 (ja) | 非常に速い皮膚及び膜浸透速度を有するｎｓａｉａプロドラッグ及びその新規医薬使用 | |
| US5530001A (en) | Pharmaceutical use of dihydropyridine derivative | |
| JP5997658B2 (ja) | 非常に速い皮膚及び膜浸透速度を有するｎｓａｉａプロドラッグ及びその新規医薬使用 | |
| JP2020520904A5 (enExample) | ||
| JP2532918B2 (ja) | グアニジノ安息香酸誘導体を有効成分として含有する抗動脈硬化剤 | |
| JPWO2021231208A5 (enExample) |